BAM
GBT

Bellevue Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bellevue Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40
Closed -$1K – 517
2022
Q2 		$1K Hold
40
– – ﹤0.01% 500
2022
Q1 		$1K Sell
40
-8
-17% -$239 ﹤0.01% 536
2021
Q4 		$1K Sell
48
-4
-8% -$124 ﹤0.01% 563
2021
Q3 		$1K Hold
52
– – ﹤0.01% 578
2021
Q2 		$2K Sell
52
-5
-9% -$195 ﹤0.01% 557
2021
Q1 		$2K Sell
57
-6
-10% -$276 ﹤0.01% 618
2020
Q4 		$3K Buy
63
+2
+3% +$99 ﹤0.01% 566
2020
Q3 		$3K Buy
61
+20
+49% +$1.27K ﹤0.01% 516
2020
Q2 		$3K Hold
41
– – ﹤0.01% 512
2020
Q1 		$3K Buy
41
+20
+95% +$1.34K ﹤0.01% 479
2019
Q4 		$2K Buy
+21
New +$1.24K ﹤0.01% 474

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Asset Management's GBT Position: Q3 2022 in Review

Bellevue Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 40 shares — an estimated $1K sold.

Bellevue Asset Management first reported a position in GBT in Q4 2019 and held it in 11 quarters. The position peaked at $3K in Q4 2020. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Bellevue Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Bellevue Asset Management sold 40 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $1K.
  • Bellevue Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 11 quarters.
  • Bellevue Asset Management's Global Blood Therapeutics, Inc. position peaked at $3K in Q4 2020.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Bellevue Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.